ONWARD Medical's Remarkable Growth in Third Quarter Achievements
EINDHOVEN – ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), a leader in neurotechnology focused on restoring movement in individuals with spinal cord injuries (SCI), has released an update on its significant accomplishments in the third quarter of 2025. As innovations in therapy advance, ONWARD Medical demonstrates the continued revolutionary impact of its technologies on patient lives.
Strong Commercial Traction in the Neurotechnology Space
In this quarter, ONWARD Medical reported phenomenal commercial traction, with 40 ARC-EX Systems sold. This impressive number reflects the growing demand for the company's external spinal cord stimulation technology. With over 50 clinics now utilizing the ARC-EX System across multiple regions, the adoption speed signifies the potential for transformation within rehabilitation practices.
What Is ARC-EX?
The ARC-EX System is designed to enhance rehabilitation efforts, providing electric spinal cord stimulation alongside functional practice to improve hand sensation and strength. This technology aims to empower patients facing challenges from their injuries, making everyday tasks more accessible.
Regulatory Milestones Highlight Company Progress
Regulatory advancements mark another pivotal segment of ONWARD's latest update. The ARC-EX System has received CE Mark certification, which allows its use both in clinical settings and at home, targeting improved hand strength and sensory functions post-injury. Additionally, the US FDA granted an investigational device exemption (IDE) for the ARC-IM System. This new approval permits the launch of the Empower BP study, evaluating the effectiveness of implanted neuromodulation in stabilizing blood pressure after SCI.
Significance of Regulatory Approvals
These certifications validate the safety and efficacy of ONWARD's devices, reassuring both medical professionals and patients of their reliability. They signify a step forward in ensuring that the therapeutic options are not only available but also backed by strong scientific evidence.
Advancements in Science and Technology
ONWARD Medical continues to solidify its position at the cutting edge of neurotechnology through notable scientific contributions. Recently, two articles spotlighting essential findings on blood pressure management after SCI were published in esteemed journals like Nature and Nature Medicine. This scholarly work bolsters the credibility and scientific foundation of the ARC-IM System, which plans to further investigate the potential of implanted devices in clinical practice.
Why Research Matters
Ongoing research and publication in reputable academic circles ensure that ONWARD Medical stays at the forefront of innovation. These advancements not only contribute to internal growth but also enhance the overall landscape of treatments available for SCI patients.
Financial Highlights Indicate Thriving Business Model
Financial performance reflects ONWARD Medical’s robust operations during Q3 2025, surpassing the EUR 1 million threshold in quarterly revenue for the first time. This achievement underscores the market acceptance of their innovative technologies and suggests an upward trajectory in the company's financial stability.
Implications for Future Growth
The financial success indicates that the company is successfully translating its strong commercial traction and innovative therapies into tangible revenue, paving the way for future investments in research and development.
Future Outlook and Commitment to Patients
CEO Dave Marver expressed confidence in the continued success of the ARC-EX System and its expansion into clinics, describing the quarter as one marked by strong execution. He looked forward to deeper insights about their progress in the next quarterly update scheduled for November. This dedication to transparency and patient care remains at the core of ONWARD's operations, as they work tirelessly to change lives through their pioneering technologies.
Community Engagement and Patient Focus
ONWARD Medical also emphasizes the importance of community feedback and engagement, creating an initiative where individuals can stay informed about ongoing studies and technologies that might benefit them. Interested parties can complete a brief form to keep up with the latest advancements.
Frequently Asked Questions
What does ONWARD Medical specialize in?
ONWARD Medical specializes in neurotechnology therapies aimed at restoring movement and function for individuals with spinal cord injuries and movement disabilities.
What is the ARC-EX System?
The ARC-EX System is an external spinal cord stimulation device designed to improve hand strength and sensation during rehabilitation.
What recent regulatory achievements has ONWARD Medical achieved?
ONWARD Medical has received CE Mark certification for the ARC-EX System and an IDE approval from the FDA for the ARC-IM System.
What significance do the recent publications hold?
The publications in high-impact journals strengthen the scientific evidence supporting ONWARD's technologies, particularly related to blood pressure management in patients post-SCI.
How can patients learn about ONWARD Medical's therapies?
Patients and those interested can fill out a form to receive updates on ongoing research studies and the availability of therapies in their area.
